US.VRTX · Vertex Pharmaceuticals

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.3,
      "details": {
        "atrPct": 3.09666239486493,
        "turnoverUsdM": 617.743885536944,
        "liquidityPoints": 0.6,
        "volatilityPoints": 0.7
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.VRTX",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 443.79,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 1,
        "rsi_score": 2.5,
        "macd_score": 1.5,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1,
      "stop_loss_percent": 6.2,
      "take_profit_price": 501.3889,
      "target_multiplier": 1.9,
      "technical_strength": 1.53,
      "take_profit_percent": 6
    },
    "positionPoints": 1.3,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 6.19332478972986,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 45.4,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 44.4,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 1
  },
  "market": {
    "ma20": 491.9795,
    "ma50": 463.7164,
    "close": 473.09,
    "prevClose": 472.57,
    "avgVolume20": 1906148,
    "volumeRatio": 0.69,
    "changePercent": 0.11
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 1,
    "details": {
      "ret_5d": -0.02662387718170456,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 1,
      "vcp_bonus": 0,
      "vol_ratio": 0.6806668195750537,
      "ret_points": 0,
      "vol_points": 0,
      "range_ratio": 0.893692890231613,
      "volat_points": 0,
      "day_range_pct": 0.026802490239087567,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 1,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 45.4,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 3.8,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 76,
        "contribution": 3.8
      },
      {
        "raw": 6.8,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 34,
        "contribution": 6.8
      },
      {
        "raw": 6,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 40,
        "contribution": 6
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 6.5,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 65,
        "contribution": 6.5
      },
      {
        "raw": 15.3,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 51,
        "contribution": 15.3
      },
      {
        "raw": 4,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 40,
        "contribution": 4
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "避免",
    "result": 44.4,
    "details": [
      "基本面分析總分: 3.8/5分",
      "資金流分析總分: 6.8/20分",
      "市場環境分析總分: 6/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 6.5/10分",
      "技術信號分析總分: 15.3/30分",
      "情緒分析: 4/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 3.8,
      "資金流": 6.8,
      "市場環境": 6,
      "情緒分析": 4,
      "技術信號": 15.3,
      "風險管理": 6.5
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "良好",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.2,
          "epsPoints": 0,
          "roePoints": 0.75,
          "debtPoints": 0.5,
          "marginPoints": 0.75,
          "turnoverUsdM": 617.743885536944,
          "volumePoints": 0.5,
          "revenuePoints": 0.4,
          "dividendPoints": 0,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 1.6,
          "mfiPoints": 0.8,
          "obvPoints": 1.6,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.VRTX",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 16.64
            }
          },
          "trend": {
            "score": 0.8,
            "details": {
              "qqq": {
                "ma20": 713.3184992500002,
                "ma50": 718.7466015999998,
                "name": "QQQ",
                "close": 691.91998,
                "points": 0.4
              },
              "spy": {
                "ma20": 745.92100485,
                "ma50": 745.0528012400001,
                "name": "SPY",
                "close": 738.16998,
                "points": 0.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 3.09666239486493,
          "atrPoints": 2,
          "cciPoints": 0.8,
          "vixPoints": 2.4,
          "marketTrendPoints": 0.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 4,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 2,
              "sentimentScoreRaw": 0.6
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 140989341,
                "url": "https://finnhub.io/api/news?id=9a4acf17d85cd62640b1ef99d26433eb4843ddd26ea54db4439b95b95e06927d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $472.57, marking a -1.96% move from the previous day.",
                "category": "company",
                "datetime": 1784757004,
                "headline": "Vertex Pharmaceuticals (VRTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know"
              },
              {
                "id": 140969778,
                "url": "https://finnhub.io/api/news?id=27a8f9b4c11fb3341b7a9d59fe254f0b38844816434279378c40ce04a712ba81",
                "image": "https://www.chartmill.com/images/uploads/Affordable_Growth_500_264px_webp_add6a3aa59.webp",
                "source": "ChartMill",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals offers affordable growth with strong double-digit earnings and revenue expansion, zero debt, and a P/E below the S&P 500 average—trading at a deep discount to biotech peers.",
                "category": "company",
                "datetime": 1784636429,
                "headline": "Vertex Pharmaceuticals (NASDAQ:VRTX): An Affordable Growth Stock Balancing Strong Fundamentals With Reasonable Valuation"
              },
              {
                "id": 140966272,
                "url": "https://finnhub.io/api/news?id=873f6ef6e8863740f15f5ee5dac12b06b5a4bce91785b0cbcd6cc716a92c8621",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $480.5, denoting a -1.06% move from the preceding trading day.",
                "category": "company",
                "datetime": 1784584806,
                "headline": "Why Vertex Pharmaceuticals (VRTX) Dipped More Than Broader Market Today"
              },
              {
                "id": 140958171,
                "url": "https://finnhub.io/api/news?id=92d5092f112f44af843f3884d48faf9004532046bab42282250b2a22dc512f2d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Earlier this month, the FDA expanded approval of Vertex Pharmaceuticals’ gene therapy Casgevy (exagamglogene autotemcel) to children aged 2 and older with sickle cell disease and transfusion-dependent thalassemia, following strong efficacy signals in two small pediatric trials. This milestone meaningfully widens access to a first-in-class gene therapy for very young patients, reinforcing Vertex’s role in genetic medicines beyond its cystic fibrosis core. We’ll examine how broadening...",
                "category": "company",
                "datetime": 1784538570,
                "headline": "How FDA’s Pediatric Expansion of Casgevy at Vertex Pharmaceuticals (VRTX) Has Changed Its Investment Story"
              },
              {
                "id": 140957169,
                "url": "https://finnhub.io/api/news?id=eff47664a09c223d3bd87244ea256a86d7edb50f9be4a91c0183fbb81ead926f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals' gene therapy exagamglogene autotemcel (Casgevy) has received expanded FDA approval. The approval now includes children as young as 2 years old with sickle cell disease or transfusion-dependent thalassemia. This decision broadens treatment options for a pediatric group with limited alternatives. For investors watching NasdaqGS:VRTX, the expanded approval highlights how Vertex Pharmaceuticals is building out its rare disease franchise around genetic medicines. The...",
                "category": "company",
                "datetime": 1784524037,
                "headline": "Vertex Pharmaceuticals (VRTX) Wins FDA Nod To Treat Children As Young As 2"
              },
              {
                "id": 140919919,
                "url": "https://finnhub.io/api/news?id=ac38e40815783f8ec5171d72b4c86aa0d5496672e10888f4bb0f5347b866864d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Get paid a guaranteed income on your Vertex shares today, which you keep no matter what, for agreeing to sell them at a higher price if the stock keeps climbing.",
                "category": "company",
                "datetime": 1784207177,
                "headline": "Collect 9.8% On VRTX Stock Now, And Still Keep 15% Of Upside"
              },
              {
                "id": 140921115,
                "url": "https://finnhub.io/api/news?id=c30edaca5af32f3105a0567a5af374e6b5c51828db4fe6b490b1d148d2a5a47e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
                "category": "company",
                "datetime": 1784206803,
                "headline": "Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It"
              },
              {
                "id": 140892612,
                "url": "https://finnhub.io/api/news?id=3d6b8baa9a83aa76e7cac3b939b0b62322f2dc6cbddd01beda9acf03fcca2fe6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (VRTX) reached $480.25 at the closing of the latest trading day, reflecting a -1.06% change compared to its last close.",
                "category": "company",
                "datetime": 1783980006,
                "headline": "Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors"
              }
            ],
            "raw_source": [
              {
                "id": 140994788,
                "url": "https://finnhub.io/api/news?id=531056513eb02609f4a4938c9a9d323461a433a76b4cbd553c5d298c12047e7a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "With its first drug on the market and a pipeline full of catalysts, the company asks investors to weigh a powerful growth story against an elevated valuation and a history of volatility.",
                "category": "company",
                "datetime": 1784818856,
                "headline": "Is Arrowhead Pharmaceuticals Stock A Smart Buy After Its Transition To A Commercial Company?"
              },
              {
                "id": 140992567,
                "url": "https://finnhub.io/api/news?id=f03ef675567d5108e942c33fea0af0f892d3babe234791d60ea6de7bc0d32119",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, which has supported the industry’s returns lately - over the past six months, healthcare stocks have gained 10%, nearly mirroring the S&P 500.",
                "category": "company",
                "datetime": 1784802168,
                "headline": "3 Healthcare Stocks with Competitive Advantages"
              },
              {
                "id": 140989341,
                "url": "https://finnhub.io/api/news?id=9a4acf17d85cd62640b1ef99d26433eb4843ddd26ea54db4439b95b95e06927d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $472.57, marking a -1.96% move from the previous day.",
                "category": "company",
                "datetime": 1784757004,
                "headline": "Vertex Pharmaceuticals (VRTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know"
              },
              {
                "id": 140988043,
                "url": "https://finnhub.io/api/news?id=4e6b58aa0243c4cf3ed6fa01c255ff8093c21f5501c6043b24f8e69611512bd7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Analysts expect new details on the lead-up to the deal “are likely to reignite” investor scrutiny that Vertex overpaid in what’s poised to be its largest-ever transaction.",
                "category": "company",
                "datetime": 1784738880,
                "headline": "Vertex was sole bidder in high-premium Crinetics acquisition"
              },
              {
                "id": 140975311,
                "url": "https://finnhub.io/api/news?id=25ea968d0976819831cb67877ca7d310eb561e52b6e6376eb848ef60154d12c1",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/21/Russell-2000-Index--Text-On-Notebook-Wit.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "Seven small-cap stocks have surged as much as 123% in early July on buyouts, FDA developments, refinancing deals and short squeezes.",
                "category": "company",
                "datetime": 1784649148,
                "headline": "These 7 Small Caps Are on Fire as the Second Half Begins: Here’s Why"
              },
              {
                "id": 140970568,
                "url": "https://finnhub.io/api/news?id=17b796c52376fef7d61ed6758f543a5b5122e8be4093a5b173e2914f2be71336",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "(American News Group News Commentary) For the millions of people who manage diabetes with daily insulin injections, the holy grail has always been the same: a therapy that senses blood sugar and releases the right amount of insulin on its own, the way a healthy pancreas does. A growing group of biotech companies is chasing that goal with cell-based therapies, and this week one small player took a concrete step toward making its version real.",
                "category": "company",
                "datetime": 1784638800,
                "headline": "A Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up"
              },
              {
                "id": 140970448,
                "url": "https://finnhub.io/api/news?id=4a0e1ac981bb5a7f38fee8acbaf68052de3d913022a498bdaffa2648573b9719",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "(Bloomberg) -- The biotechnology sector is stealing the US IPO market thunder from artificial intelligence-related listings, delivering standout returns as bankers line up a steady stream of summer debuts.Most Read from BloombergYemen’s Houthis to Impose Maritime Blockade on Saudi ArabiaChina AI Sensation Moonshot’s Gamble on Big Models Pays OffTrump Vows 50% Tariff on Canadian Goods Using Depression-Era LawMoonshot’s Kimi K3 May Be More About Memory Than ComputeUS Strikes Iran in Escalating Cam",
                "category": "company",
                "datetime": 1784637325,
                "headline": "Biotech IPO Gains Crush AI Listings With Standout 55% Return"
              },
              {
                "id": 140969778,
                "url": "https://finnhub.io/api/news?id=27a8f9b4c11fb3341b7a9d59fe254f0b38844816434279378c40ce04a712ba81",
                "image": "https://www.chartmill.com/images/uploads/Affordable_Growth_500_264px_webp_add6a3aa59.webp",
                "source": "ChartMill",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals offers affordable growth with strong double-digit earnings and revenue expansion, zero debt, and a P/E below the S&P 500 average—trading at a deep discount to biotech peers.",
                "category": "company",
                "datetime": 1784636429,
                "headline": "Vertex Pharmaceuticals (NASDAQ:VRTX): An Affordable Growth Stock Balancing Strong Fundamentals With Reasonable Valuation"
              },
              {
                "id": 140966272,
                "url": "https://finnhub.io/api/news?id=873f6ef6e8863740f15f5ee5dac12b06b5a4bce91785b0cbcd6cc716a92c8621",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $480.5, denoting a -1.06% move from the preceding trading day.",
                "category": "company",
                "datetime": 1784584806,
                "headline": "Why Vertex Pharmaceuticals (VRTX) Dipped More Than Broader Market Today"
              },
              {
                "id": 140958171,
                "url": "https://finnhub.io/api/news?id=92d5092f112f44af843f3884d48faf9004532046bab42282250b2a22dc512f2d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Earlier this month, the FDA expanded approval of Vertex Pharmaceuticals’ gene therapy Casgevy (exagamglogene autotemcel) to children aged 2 and older with sickle cell disease and transfusion-dependent thalassemia, following strong efficacy signals in two small pediatric trials. This milestone meaningfully widens access to a first-in-class gene therapy for very young patients, reinforcing Vertex’s role in genetic medicines beyond its cystic fibrosis core. We’ll examine how broadening...",
                "category": "company",
                "datetime": 1784538570,
                "headline": "How FDA’s Pediatric Expansion of Casgevy at Vertex Pharmaceuticals (VRTX) Has Changed Its Investment Story"
              },
              {
                "id": 140957169,
                "url": "https://finnhub.io/api/news?id=eff47664a09c223d3bd87244ea256a86d7edb50f9be4a91c0183fbb81ead926f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals' gene therapy exagamglogene autotemcel (Casgevy) has received expanded FDA approval. The approval now includes children as young as 2 years old with sickle cell disease or transfusion-dependent thalassemia. This decision broadens treatment options for a pediatric group with limited alternatives. For investors watching NasdaqGS:VRTX, the expanded approval highlights how Vertex Pharmaceuticals is building out its rare disease franchise around genetic medicines. The...",
                "category": "company",
                "datetime": 1784524037,
                "headline": "Vertex Pharmaceuticals (VRTX) Wins FDA Nod To Treat Children As Young As 2"
              },
              {
                "id": 140956306,
                "url": "https://finnhub.io/api/news?id=83d73f2ff98d0ae97212a4f0871c30b3aa6f32ee58d242286e4e3a28433d61cd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "The biotech's diversification efforts continue.",
                "category": "company",
                "datetime": 1784505900,
                "headline": "Vertex Pharmaceuticals Just Made a $10 Billion Acquisition Worth Watching"
              },
              {
                "id": 140921040,
                "url": "https://finnhub.io/api/news?id=b38cca16ff3fdab553b9d5e5467ff26d8301f3f124e2c0c76e4b155de1bc8e82",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "The Nasdaq 100 (^NDX) is home to some of the biggest success stories in tech and growth investing. However, certain stocks in the index face challenges like profitability concerns, rising costs, or shifts in market trends.",
                "category": "company",
                "datetime": 1784214322,
                "headline": "1 Nasdaq 100 Stock to Keep an Eye On and 2 We Question"
              },
              {
                "id": 140919919,
                "url": "https://finnhub.io/api/news?id=ac38e40815783f8ec5171d72b4c86aa0d5496672e10888f4bb0f5347b866864d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Get paid a guaranteed income on your Vertex shares today, which you keep no matter what, for agreeing to sell them at a higher price if the stock keeps climbing.",
                "category": "company",
                "datetime": 1784207177,
                "headline": "Collect 9.8% On VRTX Stock Now, And Still Keep 15% Of Upside"
              },
              {
                "id": 140921115,
                "url": "https://finnhub.io/api/news?id=c30edaca5af32f3105a0567a5af374e6b5c51828db4fe6b490b1d148d2a5a47e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
                "category": "company",
                "datetime": 1784206803,
                "headline": "Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It"
              },
              {
                "id": 140919920,
                "url": "https://finnhub.io/api/news?id=22f201450e4146a22e8d333752623c653c83dfc64ed8ec26c95bd36b95ee5206",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Technical review to strengthen subsurface model and guide next phase of developmentVANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to provide a corporate update on the ongoing technical study being completed by Lonquist Field Service (Canada), ULC (“Lonquist”) at the Company’s Robinsons River Salt Project (the “Project”), located approximately 35 kilometres south of Stephenville, Newfoun",
                "category": "company",
                "datetime": 1784203200,
                "headline": "Vortex Energy Provides Corporate Update on Robinsons River Salt Project Technical Study"
              },
              {
                "id": 140918684,
                "url": "https://finnhub.io/api/news?id=c5cd568c38c82229699ecfeff65d5f3e8af22b1b318f0d131623d8f2582c384d",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2190808580/image_2190808580.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "VRTX",
                "summary": "The curing sickle cell through gene therapy story is a long way from being written. But it’s for sure that it has not gone like some of its participants have wanted it to. Read more here...",
                "category": "company",
                "datetime": 1784187000,
                "headline": "The Battle For Sickle Cell"
              },
              {
                "id": 140925193,
                "url": "https://finnhub.io/api/news?id=a1e97ddb4115cd5f851ad1b2dcb8625c247944437da76f2f5a37275be9ebfa7d",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_4.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 7.55% on an annualized basis producing an average annual return of 19.41%. Currently, Vertex Pharmaceuticals has a market",
                "category": "company",
                "datetime": 1784135733,
                "headline": "$1000 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today"
              },
              {
                "id": 140911439,
                "url": "https://finnhub.io/api/news?id=a706d9b34a32e9ee4e72c8bb0e5c93ecc188bc198255ecbd232c037a410bf5d7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "An ETF's label tells you the category, but the real story is always in the portfolio's actual shape.",
                "category": "company",
                "datetime": 1784132585,
                "headline": "IBB ETF Holds Fewer Bets Than You Think"
              },
              {
                "id": 140909807,
                "url": "https://finnhub.io/api/news?id=894eb83bae3b7701338821979d336d28e14b5029ab6a7dc8a0330d7df2b3d9fb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) is one of the 10 affordable biotech stocks to buy right now. On July 6, Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) and Vertex Pharmaceuticals announced that both companies have agreed to a definitive agreement, according to which Vertex will acquire Crinetics Pharmaceuticals. The deal is priced at $85 a share in cash consideration, […]",
                "category": "company",
                "datetime": 1784124103,
                "headline": "Vertex to Acquire Crinetics Pharmaceuticals (CRNX) in $85 Per Share Cash Deal"
              },
              {
                "id": 140897048,
                "url": "https://finnhub.io/api/news?id=8fd522063fde651778f609334b93b87ac175d51b99792eac01e61e5ec2bdd003",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex's $10 billion acquisition may have spooked investors, given how rich it appeared to be.",
                "category": "company",
                "datetime": 1784031600,
                "headline": "Here's Why Vertex Was Willing to Pay a Premium of More Than 100% for Crinetics Pharmaceuticals"
              },
              {
                "id": 140892612,
                "url": "https://finnhub.io/api/news?id=3d6b8baa9a83aa76e7cac3b939b0b62322f2dc6cbddd01beda9acf03fcca2fe6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (VRTX) reached $480.25 at the closing of the latest trading day, reflecting a -1.06% change compared to its last close.",
                "category": "company",
                "datetime": 1783980006,
                "headline": "Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors"
              },
              {
                "id": 140891369,
                "url": "https://finnhub.io/api/news?id=cd9d911d1d1ddc04410b592e494aed229ad87f0921faa2794983c8582dbd1465",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, July 13, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) announces that it has closed its previously announced non-brokered private placement financing (the “Private Placement”). The Company issued an aggregate of 5,000,000 units of the Company (the “Units”) at a price of $0.30 per Unit for gross proceeds of $",
                "category": "company",
                "datetime": 1783979160,
                "headline": "Vortex Energy Corp. Announces Closing of LIFE Offering"
              },
              {
                "id": 140889916,
                "url": "https://finnhub.io/api/news?id=e8a7de07cc162dea1ae6251224928f62de69baad025c1e8b989c861cc24f2a14",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals recently announced its largest-ever acquisition.",
                "category": "company",
                "datetime": 1783968427,
                "headline": "Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?"
              },
              {
                "id": 140891092,
                "url": "https://finnhub.io/api/news?id=7de8e9d2f4590eeb57173c106d795ec9e57e4287831ea47e3a3f0eb5dc45f49e",
                "image": "",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "UBS  analyst Michael Yee   maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $545 to $585.",
                "category": "company",
                "datetime": 1783952283,
                "headline": "UBS Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $585"
              },
              {
                "id": 140891370,
                "url": "https://finnhub.io/api/news?id=03bcc91f3ed155fa3ddcb91bbc261b06b7a6a3b1554a720faace2ae6851096e3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals will release its second-quarter earnings next month, and analysts anticipate a single-digit bottom-line growth.",
                "category": "company",
                "datetime": 1783951045,
                "headline": "What to Expect From Vertex Pharmaceuticals' Next Quarterly Earnings Report"
              },
              {
                "id": 140891093,
                "url": "https://finnhub.io/api/news?id=fd93aff66889dc24055c8b99639e5acc340f6629383543951e341c24f0b63207",
                "image": "",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "Truist Securities  analyst Danielle Brill   maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $542 to $560.",
                "category": "company",
                "datetime": 1783945862,
                "headline": "Truist Securities Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $560"
              },
              {
                "id": 140874823,
                "url": "https://finnhub.io/api/news?id=74393636e844e518614a2f2bbc4b00f4b95cda8bb29e624da6373305bfa8aab5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (NasdaqGS:VRTX) received expanded FDA approval for CASGEVY, extending use to children as young as 2 years with sickle cell disease and beta thalassemia. The company also signed a Letter of Intent with Canadian national payers that outlines commercial access terms for ALYFTREK, its next generation cystic fibrosis therapy. These updates arrive as Vertex Pharmaceuticals trades around $485.39 and remains closely watched after a 140.0% return over the past 5 years and a...",
                "category": "company",
                "datetime": 1783826346,
                "headline": "Vertex (VRTX) Wins FDA Expansion For CASGEVY And Advances ALYFTREK In Canada"
              },
              {
                "id": 140873536,
                "url": "https://finnhub.io/api/news?id=e9086ad552f75890511f4f50816a1086a025168d4d5bcc85a6530a23c82a78c6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (NASDAQ:VRTX) said it has entered into a definitive agreement to acquire Crinetics Pharmaceuticals for $85 per share in cash, a transaction Vertex executives described as a strategic expansion into specialty endocrinology. On a conference call announcing the deal, Vertex CEO",
                "category": "company",
                "datetime": 1783803729,
                "headline": "Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse"
              },
              {
                "id": 140866271,
                "url": "https://finnhub.io/api/news?id=3474024df282bf83c2487827c06844fbdf81b888de20d743220ca244b809d07e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "It's been a volatile year for the company, but don't let that scare you away.",
                "category": "company",
                "datetime": 1783718400,
                "headline": "Is This Biotech Stock a Buy Near Its 52-Week High?"
              },
              {
                "id": 140865211,
                "url": "https://finnhub.io/api/news?id=c9b07089322e23d06265dae52c2992c333bdcda8fef02ebe98f458bef38d5d1f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "It is getting acquired by a larger firm in the sector.",
                "category": "company",
                "datetime": 1783711352,
                "headline": "Why This Pharmaceutical Stock Jumped Close to 100% This Week"
              },
              {
                "id": 140861703,
                "url": "https://finnhub.io/api/news?id=af70857a11cc855d135aa4dbacdfb09561eefbc7830e6114b9d2980a93d0ad6f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.",
                "category": "company",
                "datetime": 1783686601,
                "headline": "If You Invested $1000 in Vertex Pharmaceuticals a Decade Ago, This is How Much It'd Be Worth Now"
              },
              {
                "id": 140861704,
                "url": "https://finnhub.io/api/news?id=261335ddb3a4405ad09573cc88858404a83f044cb91dc30fe6fb403e911b1373",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "With its lead drug driving rapid growth and three more on deck, the biotech is betting it can outrun future competition and a history of volatility.",
                "category": "company",
                "datetime": 1783685653,
                "headline": "Beyond The Breakout Drug: Is BridgeBio Pharma Stock A Buy On Its Next Act?"
              },
              {
                "id": 140860831,
                "url": "https://finnhub.io/api/news?id=70bace5e39146e0e64ac0773b15c6a491cc88cb329eb3be14cd2305070834fcd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "A look at the company's history of deep drawdowns shows the real risk shareholders are carrying today.",
                "category": "company",
                "datetime": 1783683335,
                "headline": "The Long Climb Back For Ionis Stock"
              },
              {
                "id": 140859839,
                "url": "https://finnhub.io/api/news?id=cdd9c810230d73c852b260a9d4bceec99d4b0eebc8f9e6457c65267d2e0ad5c7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Additional blockbuster drugs may be on the horizon.",
                "category": "company",
                "datetime": 1783671900,
                "headline": "Vertex Pharmaceuticals Just Made a $10 Billion Move. Is the Stock a Buy?"
              },
              {
                "id": 140854805,
                "url": "https://finnhub.io/api/news?id=73dd4ee0879bf24374581d5aa1a77260cfbe8b63a6339577b193b70be26a497b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (NASDAQ:VRTX) is one of the best QQQ Stocks to invest in. On July 1, Vertex Pharmaceuticals announced that the US FDA approved the expanded use of its genetic therapy, CASGEVY, to treat children as young as 2 years old. This makes it the first and only approved gene therapy for patients of this […]",
                "category": "company",
                "datetime": 1783622227,
                "headline": "Vertex (VRTX) is One of the Best QQQ Stocks to Invest in"
              },
              {
                "id": 140853379,
                "url": "https://finnhub.io/api/news?id=af8f4e5d4bf20131bde841c0314c7a25c154ef1a511b44e077f6a59cd29c3986",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Crinetics Pharmaceuticals (NASDAQ:CRNX) shares have climbed 99% just this week, from $42.03 at Monday’s close, to $83.54 earlier today. The simple reason: Vertex Pharmaceuticals (NASDAQ:VRTX) agreed to acquire it. Vertex’s $10 Billion All-Cash Bid Fuels the Surge The catalyst arrived after the market close on July 6: Vertex agreed to buy Crinetics for approximately $10 ... Why Crinetics Stock Soared 99% This Week",
                "category": "company",
                "datetime": 1783618179,
                "headline": "Why Crinetics Stock Soared 99% This Week"
              },
              {
                "id": 140852010,
                "url": "https://finnhub.io/api/news?id=553e10dc88f8db461878d38f0666f117101c8f854c6a22e5273fb7ce1784b80d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "CNBC’s Jim Cramer pushed viewers away from the usual semiconductor and hyperscaler chatter. Instead, he highlighted a group he says has quietly become the market’s leader. “There is a move in biotech that we have not talked about at all that is really extraordinary, and particularly since the change at the head of the FDA,” ... Jim Cramer Says Biotech is The Hottest Group in The Market Right Now",
                "category": "company",
                "datetime": 1783611325,
                "headline": "Jim Cramer Says Biotech is The Hottest Group in The Market Right Now"
              },
              {
                "id": 140852138,
                "url": "https://finnhub.io/api/news?id=ff73aa141d7117de4953b3a8c5dac95fb022c08cd27a3ad995d33e371ff05606",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "The cystic fibrosis market is expanding due to rising disease prevalence and advancements in targeted therapies and precision medicine. Predominantly affecting Western populations, over 30,000 people in the U.S. live with this genetic disorder. The demand for cystic fibrosis therapies is driven by new treatments and an aging population. CFTR modulator therapies have significantly improved patient outcomes by targeting mutations in the CFTR gene. While novel treatments provide hope, high costs an",
                "category": "company",
                "datetime": 1783610760,
                "headline": "Cystic Fibrosis Market, Global & Regional Now Available; Profiles Vertex Pharmaceuticals, AbbVie, and Other Frontrunner Competitors in Orphan Drug Markets"
              },
              {
                "id": 140859174,
                "url": "https://finnhub.io/api/news?id=c227e9fb11d31a3021a091175fdb43fac55c743eccee1f8a273f64ab8ad8c2db",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "International Biotechnology Trust (LSE:IBT) portfolio manager Ailsa Craig joined Proactive's Stephen Gunnion to discuss the surge in biotech M&A activity, following Vertex Pharmaceuticals' acquisition of Crinetics at a 102% premium. Craig said the deal wave reflects a structural dynamic: most new drugs now originate from biotech, while large pharmaceutical companies face a significant wave of patent expiries and hold substantial cash resources. Vertex's move into rare diseases and chronic therapies makes strategic sense as it diversifies beyond its cystic fibrosis franchise — and the premium paid reflected Crinetics' strong independent position. \"They would be perfectly happy to stay independent. And Vertex had to pay up if they wanted to buy them,\" Craig said. She outlined how IBT evaluates investments using many of the same criteria as pharma business development teams — focusing on chronic therapies, attractive valuations, strong intellectual property and companies capable of remaining independent, making them compelling acquisition targets. Around 40% of IBT's portfolio currently meets these criteria, compared with around 10% of its benchmark - a positioning Craig believes leaves the trust well placed to benefit from continued industry consolidation. Visit the Proactive YouTube channel for more interviews with leading companies and investment experts. If you enjoyed this video, please like, subscribe to the channel and enable notifications so you never miss future content. #InternationalBiotechnologyTrust #Biotech #Biotechnology #AilsaCraig #HealthcareInvesting #BiotechStocks #Pharma #Vertex #Crinetics #MergersAndAcquisitions #Investing #StockMarket #LifeSciences #PatentExpiry #HealthcareInnovation #ProactiveInvestors",
                "category": "company",
                "datetime": 1783599944,
                "headline": "IBT portfolio manager: biotech M&A boom set to continue as big pharma hunts"
              },
              {
                "id": 140848791,
                "url": "https://finnhub.io/api/news?id=7d568a47c8ad16b91d73b1c96aa5bfe5a734482183673771b763e535d2afd1c4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage have propelled their returns.",
                "category": "company",
                "datetime": 1783583340,
                "headline": "1 Momentum  Stock to Research Further and 2 Facing Headwinds"
              },
              {
                "id": 140851993,
                "url": "https://finnhub.io/api/news?id=10ee6961d749320bbe6f5493aa7cd89e579980c9c25c75c0a3637ceb4d7cec88",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/09/Nvidia-logo-on-smartphone-screen-with-Ch.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "The Halftime Report Final Trades featured stock picks from Bryn Talkington, Jim Lebenthal, Liz Young Thomas, and Joseph M. Terranova.",
                "category": "company",
                "datetime": 1783583115,
                "headline": "Nvidia, Vertex Pharmaceuticals And More On CNBC’s ‘Final Trades’"
              },
              {
                "id": 140847591,
                "url": "https://finnhub.io/api/news?id=b51355813fb0db28e4890bf556e8770afbd41f58f0985074d5473b6d81753f73",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Penguin Solutions, Arista Networks, and Biocryst Pharmaceuticals surged to 52-week highs on Wednesday amid a rotation into technology and healthcare stocks.",
                "category": "company",
                "datetime": 1783568379,
                "headline": "Why Did PENG, ANET, BCRX Shares Surge To 52-Week Highs?"
              },
              {
                "id": 140841649,
                "url": "https://finnhub.io/api/news?id=46cf1067762772bdaff0bf3cd43eb85b6816d116b9c6119f06b2aaa77d698dba",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Biopharma sector's performance in H2 is expected to be driven more by company fundamentals rather th",
                "category": "company",
                "datetime": 1783523510,
                "headline": "Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says"
              },
              {
                "id": 140841830,
                "url": "https://finnhub.io/api/news?id=496b1ff88d3330c5cf8f0e9db6cf6769f8a09a0ceae7d543fd0f2e908dbb4915",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "We recently compiled a list of the 10 Best Innovative Healthcare Stocks to Buy Now. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is one of the best healthcare stocks on our list. TheFly reported on July 2 that UBS analyst Ashwani Verma initiated coverage of CRNX with a Buy rating and a $55 price target. The analyst noted that […]",
                "category": "company",
                "datetime": 1783523080,
                "headline": "Is Crinetics Pharmaceuticals, Inc. (CRNX) Stock a Buying Opportunity After a 44% Pullback?"
              },
              {
                "id": 140842715,
                "url": "https://finnhub.io/api/news?id=c8f467e1ed158fcec22bad8db27051c262b7c5c889f593124c45188044a6eec0",
                "image": "https://image.cnbcfm.com/api/v1/image/108332237-17835306111783530602-47038414389-1080pnbcnews.jpg?v=1783530610&w=1920&h=1080",
                "source": "CNBC",
                "related": "VRTX",
                "summary": "Mike Akins, ETF Action founding partner, joins 'Halftime Report' to discuss the under-appreciated market trades, catch up trades for the rest of the year and much more.",
                "category": "company",
                "datetime": 1783516859,
                "headline": "Software and cloud computing names have strong growth scenarios, says ETF Action's Mike Akins"
              },
              {
                "id": 140840572,
                "url": "https://finnhub.io/api/news?id=c206e2009193c9aaa77cf09239f7c877b0a9f0a5dffa3fef4e2ae51a1758d667",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals stock has delivered a strong 163.3% return over the past 5 years, and the latest Discounted Cash Flow (DCF) intrinsic value estimate now points to meaningful upside relative to the current share price, even though market based valuation checks look more balanced. Over 5 years, a 163.3% total return suggests investors have already priced in a lot of success for Vertex Pharmaceuticals, which raises the bar for any further potential upside. The planned US$10b acquisition...",
                "category": "company",
                "datetime": 1783516331,
                "headline": "Vertex (VRTX) Stock May Be 36% Undervalued Following Its $10b Deal"
              },
              {
                "id": 140842570,
                "url": "https://finnhub.io/api/news?id=ee1ffe5e8d5a6325b6d11f969a0327c5fedc224009f46d9e761ed327ef11e409",
                "image": "https://image.cnbcfm.com/api/v1/image/108332231-17835301031783530100-47038298545-1080pnbcnews.jpg?v=1783530102&w=1920&h=1080",
                "source": "CNBC",
                "related": "VRTX",
                "summary": "The Investment Committee give you their top stocks to watch for the second half.",
                "category": "company",
                "datetime": 1783515957,
                "headline": "Final Trades: Vertex, Nvidia, the DRAM and the VNQ"
              },
              {
                "id": 140851013,
                "url": "https://finnhub.io/api/news?id=da4341664338040440e42f161261d5e9008e268c4ca8a1137f20bf5b9e730807",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals will acquire Crinetics Pharmaceuticals for $10 billion at $85 per share, adding the approved drug PALSONIFY and pipeline candidate Atumelant to expand beyond its cystic fibrosis franchise.",
                "category": "company",
                "datetime": 1783515900,
                "headline": "Vertex’s Crinetics Deal Balances Growth with Integration Risk"
              },
              {
                "id": 139934456,
                "url": "https://finnhub.io/api/news?id=188b4d8ee71a8e52b66809d406cc7c293d8b00b7f1c9f28a4df221dd0b53d09c",
                "image": "",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "",
                "category": "company",
                "datetime": 1783515679,
                "headline": "Hesai Says Co Selected By NVIDIA As Lidar Partner For NVIDIA DRIVE Hyperion 10"
              },
              {
                "id": 140840573,
                "url": "https://finnhub.io/api/news?id=5e139a297017ff79fead3a17df77dd2984859059085fd34751ce71e2a30a986a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Get paid a guaranteed income on your Vertex shares today, which you keep no matter what, for agreeing to sell them at a higher price if the stock keeps climbing.",
                "category": "company",
                "datetime": 1783514909,
                "headline": "Collect 9.0% On VRTX Stock Now, And Still Keep 15% Of Upside"
              },
              {
                "id": 140840574,
                "url": "https://finnhub.io/api/news?id=f820520193374e48e28b94a6e505d718214ae560811fdc586e1e0d09fff0c376",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (VRTX) has moved into the spotlight after agreeing to acquire Crinetics Pharmaceuticals for about $10 billion in cash, a rare disease focused deal that immediately broadens its endocrinology footprint. See our latest analysis for Vertex Pharmaceuticals. Vertex Pharmaceuticals' latest share price of US$522.25 sits close to recent highs, with a 30 day share price return of 16.88% and a 1 year total shareholder return of 11.98%, adding to a 163.32% total shareholder return...",
                "category": "company",
                "datetime": 1783512691,
                "headline": "Vertex Pharmaceuticals (VRTX) Buys Crinetics, Where Does Fair Value Sit Now?"
              },
              {
                "id": 140838993,
                "url": "https://finnhub.io/api/news?id=093edf349b6b567d5c293f0ac8a8491b0d399e592d30167978955680c4d1379b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for about US$10b, reigniting takeover speculation across the obesity drug sector. Following this deal, Viking Therapeutics (NasdaqCM:VKTX) has drawn fresh attention as a possible M&A target. Investor focus is increasing on upcoming data for VK2735 and the recently initiated Phase 1 trial of VK3019. Viking Therapeutics sits at the intersection of obesity and metabolic drug development, an area that has attracted large capital...",
                "category": "company",
                "datetime": 1783501955,
                "headline": "Viking Therapeutics (VKTX) Draws Takeover Focus After Vertex's $10 Billion Crinetics Deal"
              },
              {
                "id": 140838994,
                "url": "https://finnhub.io/api/news?id=42e20c4f78b5d7fa6b079afa6f31b4bfe9537928845ffa1814e1302bc78586e7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "This buy gives Vertex both a recently-commercialized drug, and a very strong lead candidate.",
                "category": "company",
                "datetime": 1783496933,
                "headline": "Vertex Is Paying a 102% Premium to Acquire Crinetics for $10 Billion. Here's Whether the Deal Is Worth It."
              },
              {
                "id": 140838995,
                "url": "https://finnhub.io/api/news?id=2302cd588f2b9ed71e70e8e266ac65567ea81fef90aa851924a7e09285d9f136",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "CRINETICS PHARM (CRNX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.",
                "category": "company",
                "datetime": 1783493520,
                "headline": "Strength Seen in CRINETICS PHARM (CRNX): Can Its 98.7% Jump Turn into More Strength?"
              },
              {
                "id": 140837926,
                "url": "https://finnhub.io/api/news?id=a70293ebe98e19e67dedeb8cf9ce371a3c1d5aa0848d769bd645f7d54e878082",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Wall Street sees bigger upside in VKTX, with Koyfin’s average target implying 120% upside versus 99% for BCRX.",
                "category": "company",
                "datetime": 1783487516,
                "headline": "VKTX Vs BCRX: Which Biotech Takeover Favorite Offers More Upside After Vertex’s $10B CRNX Deal?"
              },
              {
                "id": 140837513,
                "url": "https://finnhub.io/api/news?id=302924a36eab9926010fffab59b808557440262affead14cf63dfd8c0e1baeda",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Investors favored companies benefiting from biotech deals, rising power demand from AI data centers, and cost-cutting efforts to improve profits.",
                "category": "company",
                "datetime": 1783481690,
                "headline": "Why Did CRNX, D, BCRX Stocks Surge To 52-Week Highs Today?"
              },
              {
                "id": 140837469,
                "url": "https://finnhub.io/api/news?id=b41fefdad013a03f064cf0678a488c23051e8ccf264f74d11beba5bc943475a2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "The drugmaker is paying up for a new growth engine. Is the price disciplined?",
                "category": "company",
                "datetime": 1783480800,
                "headline": "Vertex Is Buying Crinetics for $10 Billion. Here's What Investors Need to Know."
              },
              {
                "id": 140837515,
                "url": "https://finnhub.io/api/news?id=988fe71e303ec83078bc381eddbb7fd02400f18abf469139ca5464ab1e83974a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Crinetics stock nearly doubled after Vertex agreed to buy it for $10 billion. What's behind the deal, and is it worth it?",
                "category": "company",
                "datetime": 1783480141,
                "headline": "Why Crinetics Stock Doubled After Vertex’s $10 Billion Buyout"
              },
              {
                "id": 140836545,
                "url": "https://finnhub.io/api/news?id=7ba3abe3ae1625e355c2830d91d3a21de9e5402e5d28ee8f3025463f835c5589",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (VRTX) closed at $522.25 in the latest trading session, marking a -1.39% move from the prior day.",
                "category": "company",
                "datetime": 1783461606,
                "headline": "Vertex Pharmaceuticals (VRTX) Registers a Bigger Fall Than the Market: Important Facts to Note"
              },
              {
                "id": 140835479,
                "url": "https://finnhub.io/api/news?id=8280e2e479d67e2480a6b07e516a44aa2f83a2ce7e43ac27edbcf166b365c0cb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (NasdaqGS:VRTX) agreed to acquire Crinetics Pharmaceuticals for US$10b. The deal adds a marketed rare disease drug and moves Vertex into endocrinology as a new business area. The transaction is positioned to expand Vertex's portfolio beyond its existing core franchises. Vertex Pharmaceuticals has built its business around treatments for rare and serious diseases, and the planned Crinetics acquisition marks a shift into endocrinology with an FDA approved therapy and...",
                "category": "company",
                "datetime": 1783455716,
                "headline": "Vertex (VRTX) Is Buying Crinetics For $10 Billion And Entering Endocrinology"
              },
              {
                "id": 140835480,
                "url": "https://finnhub.io/api/news?id=32f8fcb1eaad62c124d29a25a84e691fb7f1f29825e76b0b1eebbbb987ca4a72",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "BOSTON, July 07, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2026 financial results on Monday, August 3, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the \"Vertex Pharmaceuticals Second Quarter 2026 Earnings Call.\"",
                "category": "company",
                "datetime": 1783454400,
                "headline": "Vertex to Announce Second Quarter 2026 Financial Results on August 3rd"
              },
              {
                "id": 140835352,
                "url": "https://finnhub.io/api/news?id=cde7c44a0e7ab15b40a678d6dc96c3f9be5c0f283a2690eb28957cfa2f295b37",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index and the State S",
                "category": "company",
                "datetime": 1783453906,
                "headline": "Sector Update: Healthcare Stocks Gain Late Afternoon"
              },
              {
                "id": 140834318,
                "url": "https://finnhub.io/api/news?id=4e9ef5791e5b2a2d1c19e57073528d609a4e42146820cba80a95535569ffa69a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "An all-cash deal at $85 per share adds an FDA-approved acromegaly pill",
                "category": "company",
                "datetime": 1783450318,
                "headline": "Vertex Pays $10 Billion to Enter Rare Endocrine Disease"
              },
              {
                "id": 140833117,
                "url": "https://finnhub.io/api/news?id=6b103d3f540e5f36b2a1fe66606bdfcb34a21bef507ed05b89e2282c9c0ef2b1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (VRTX) and Crinetics Pharmaceuticals (CRNX) said late Monday they have reache",
                "category": "company",
                "datetime": 1783445779,
                "headline": "Top Midday Gainers"
              },
              {
                "id": 140832952,
                "url": "https://finnhub.io/api/news?id=a07c9c4cef97cce487e30f32d0b1056e59bd7c136669ff319a0aef87895b94ee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "On CNBC’s Mad Dash segment on Monday, July 6, 2026, Jim Cramer made one of his most bullish biotech calls in years, arguing that the sector could be entering a new wave of mergers and acquisitions as the regulatory environment becomes more favorable for dealmaking. “There is a move in biotech that we have not ... Jim Cramer Calls Biotech “The Hottest Group in the Market” as He Predicts “Deals Are Going to Be Flooding the Market”",
                "category": "company",
                "datetime": 1783441817,
                "headline": "Jim Cramer Calls Biotech “The Hottest Group in the Market” as He Predicts “Deals Are Going to Be Flooding the Market”"
              },
              {
                "id": 140831208,
                "url": "https://finnhub.io/api/news?id=f1ee1f2e8c1fd17d1633be73a2c1668c06c85cf4fbafeaf8fcc4f8d5c6c0829f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "All three major US stock indexes were down in late-morning trading Tuesday, with the Nasdaq Composit",
                "category": "company",
                "datetime": 1783439032,
                "headline": "Top Midday Stories: Amazon Seeking at Least $25 Billion From US Bond Sale; Fiserv Explores Sale of STAR Debit Network"
              },
              {
                "id": 140831571,
                "url": "https://finnhub.io/api/news?id=fd4cfb9cc3d3f9c492421fc560dd27520cdb70922e902008693b53b70a690777",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "One has FDA approval and revenue; the other is pre-commercial but debt-free. Both face distinct risks that could reshape your biotech bet.",
                "category": "company",
                "datetime": 1783436212,
                "headline": "CRISPR Therapeutics vs. Viking Therapeutics: Is a Gene-Editing or Weight Loss Focused Stock Is a Better Buy in 2026?"
              },
              {
                "id": 140831572,
                "url": "https://finnhub.io/api/news?id=a38981dea90aa6ee37cb87bf3739ffe86ace6009025274a29e968a0aacfd5895",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "H.C. Wainwright said Crinetics’ lead product Palsonify adds a meaningful commercial product and establishes endocrinology as Vertex’s fifth major business pillar.",
                "category": "company",
                "datetime": 1783432786,
                "headline": "Crinetics Acquisition Creates A ‘Fifth Commercial Pillar’ For Vertex, Says Analyst – Why HC Wainwright Sees A 24% Upside Potential In VRTX Stock"
              },
              {
                "id": 140831573,
                "url": "https://finnhub.io/api/news?id=bca90c08c5290d0b057aea4f48f97dd4c108c16a4c261af6221185093ff4e309",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex to acquire CRNX for $10B, adding approved rare disease drug Palsonify and late-stage pipeline assets to expand its endocrinology portfolio.",
                "category": "company",
                "datetime": 1783430760,
                "headline": "VRTX to Strengthen Rare Disease Portfolio With $10B Crinetics Buyout"
              },
              {
                "id": 140832339,
                "url": "https://finnhub.io/api/news?id=46c5e09411d8bcbed1515bf6da0dbfca71752d4b52eb881dd94a2e11b591e58c",
                "image": "https://image.cnbcfm.com/api/v1/image/108321360-17812891372026-06-12t182423z_83870851_rc2fslai0haj_rtrmadp_0_spacex-ipo-california.jpeg?v=1781289188&w=1920&h=1080",
                "source": "CNBC",
                "related": "VRTX",
                "summary": "Here are some of the companies making headlines in midday trading.",
                "category": "company",
                "datetime": 1783428319,
                "headline": "Stocks making the biggest moves midday: SpaceX, GE Vernova, Crinetics Pharmaceuticals, Rivian & more"
              },
              {
                "id": 140830197,
                "url": "https://finnhub.io/api/news?id=cd09cc813c3c771f401b16333afdcc9fbe21d5fcde3dba55ef6ac7f8034d3b94",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Monday agreed to acquire Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) for $85 per share in cash, a total equity value of approximately $10 billion ($8.8 billion net of cash). Vertex expects to finance the acquisition using a combination of cash on hand and debt, supported by $4.5 billion of fully committed bridge financing. Vertex’s cash, cash equivalents, and total marketable securities as of March 31, 2026, were $13.0 billion. Read Also: Ver",
                "category": "company",
                "datetime": 1783427054,
                "headline": "Vertex Sees Over $5 Billion Peak Sales Potential From Crinetics Assets"
              },
              {
                "id": 140830198,
                "url": "https://finnhub.io/api/news?id=07741b6d9ed1ef64dc4112e20a34185f5ee95ea4ce76d750ea936acd7718c790",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "The deal gives Vertex access to Palsonify, an oral acromegaly treatment, and atumelnant, a late-stage drug for congenital adrenal hyperplasia",
                "category": "company",
                "datetime": 1783426448,
                "headline": "Vertex Pharmaceuticals buying Crinetics for $10 billion"
              },
              {
                "id": 140829988,
                "url": "https://finnhub.io/api/news?id=3df760343f3160232fa4c72510327f355b63e953c2276f98c9574732cbf60b54",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "US equity futures were mostly pointing lower before the open Tuesday amid a broad sell-off in chip s",
                "category": "company",
                "datetime": 1783425801,
                "headline": "Equities Mostly Down Pre-Bell Amid Broad Chip Stock Sell-Off"
              },
              {
                "id": 140830040,
                "url": "https://finnhub.io/api/news?id=a5b5e4e6b022f571a62060f2e158d7ad3e421639d3865c95e74941408264af92",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "AI stocks take a beating, with South Korean memory-chip maker Samsung Electronics setting the tone for the broader market.",
                "category": "company",
                "datetime": 1783425720,
                "headline": "Intel, Corning, Super Micro, and More Stocks That Explain Today’s Market"
              },
              {
                "id": 140834389,
                "url": "https://finnhub.io/api/news?id=f8120fe284a14c42bac7f9ab2142d824404d9d2fac35fa4ba4bb5bb2415a3974",
                "image": "",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "RBC Capital  analyst Brian Abrahams   maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Outperform and raises the price target from $543 to $570.",
                "category": "company",
                "datetime": 1783424787,
                "headline": "RBC Capital Maintains Outperform on Vertex Pharmaceuticals, Raises Price Target to $570"
              },
              {
                "id": 140830042,
                "url": "https://finnhub.io/api/news?id=febf7ff565571596fdd064dd468b61ee976bf7804853ede03ddb2439477a3ade",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "(Bloomberg) -- US stock futures pointed to renewed weakness in technology shares after Samsung Electronics Co.’s earnings failed to satisfy investors, renewing pressure on chipmakers across global markets.Most Read from BloombergGreece Offers Bounty to Catch Ravenous Fish Lured by Warming SeaMicrosoft’s Xbox to Cut 3,200 Jobs, Divest Five Studios in Major OverhaulTwo Millennium Trading Pods Made About $3.7 Billion Last MonthSaudis Slash Main Oil Price to Rare Discount as Market DivesChina Senten",
                "category": "company",
                "datetime": 1783424433,
                "headline": "Tech Weakness Resumes After Samsung Misses Lofty AI Expectations"
              },
              {
                "id": 140830202,
                "url": "https://finnhub.io/api/news?id=2f55323c8d907b3bb40ad16b1905f12be42beb246018ca38ce78779ee8105690",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Crinetics Pharmaceuticals  stock was surging on Tuesday after  Vertex Pharmaceuticals  said it had agreed to buy the biotech for $10 billion.  Vertex slid 1.2%.  Vertex said in a press release late Monday that it would buy Crinetics, which specializes in discovering and developing treatments for endocrine diseases, for $85 a share in cash.",
                "category": "company",
                "datetime": 1783423980,
                "headline": "This Biotech Stock Is Soaring 99% After Vertex Agrees to Takeover Deal"
              },
              {
                "id": 140829214,
                "url": "https://finnhub.io/api/news?id=155cc42b2de9b601d259fb80cc11c90f2af57de44efa1c5cc9025478d67725b8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (VRTX) agreed to acquire endocrine disease drugmaker Crinetics Pharmaceutical",
                "category": "company",
                "datetime": 1783422371,
                "headline": "Vertex Pharmaceuticals to Buy Crinetics in $10 Billion Deal"
              },
              {
                "id": 140829215,
                "url": "https://finnhub.io/api/news?id=6e62de35aca323dad3b8e253120c4385722cfe9e12ce4d1d34f033e9d96c5f74",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "The acquisition is expected to close in the third quarter of 2026.",
                "category": "company",
                "datetime": 1783421730,
                "headline": "Vertex signs agreement to acquire Crinetics for $10bn"
              },
              {
                "id": 140829115,
                "url": "https://finnhub.io/api/news?id=e92e9ac4ecb469082683b27e468d358b772ad7fb4beab6459bfba2c132333c7f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "AI stocks take a beating, with South Korean memory-chip maker Samsung Electronics setting the tone for the broader market.",
                "category": "company",
                "datetime": 1783420500,
                "headline": "Samsung, Micron, Rivian, SpaceX, Crinetics, and More Stocks That Explain Today’s Market"
              },
              {
                "id": 140829217,
                "url": "https://finnhub.io/api/news?id=f02fd4b54d91f01b651eff4be45b804765c5595587e6efb6cab6112e9600e9dc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Crinetics Pharmaceuticals stock has delivered a strong 112.8% return over the past three years, yet its valuation checks paint a mixed picture at the same time as investors weigh the agreed US$85 per share cash acquisition by Vertex Pharmaceuticals against the current market pricing. Over the last three years, Crinetics Pharmaceuticals has returned 112.8%, which puts recent gains in the context of a longer period of substantial shareholder returns. Vertex's planned US$10b cash acquisition,...",
                "category": "company",
                "datetime": 1783419426,
                "headline": "Crinetics (CRNX) Stock Could Be Overvalued After Its 113% Run"
              },
              {
                "id": 140830465,
                "url": "https://finnhub.io/api/news?id=e0b7e923d5f8e72f7db716b335ec70d8a45cdc7266f8d8f0ebc5eb2bc6f6bc3f",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/464406694/image_464406694.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "VRTX",
                "summary": "Q2 of 2026 started with a white-hot rally in the stock market, recovering its losses from the first quarter and setting several record highs throughout April (+10.4%) and May (+5.15).",
                "category": "company",
                "datetime": 1783419120,
                "headline": "Andrew Hill Investment Advisors' Q2 2026 Significant Positions"
              },
              {
                "id": 140830203,
                "url": "https://finnhub.io/api/news?id=75014b57a5eaea585df8853c5a378ed4fa238d1cdac808c53590a990dc26c001",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex claimed the two drugs in the deal could eventually bring in more than $5 billion annually. Still, the high price it paid stirred debate among analysts and investors.",
                "category": "company",
                "datetime": 1783417140,
                "headline": "Vertex to acquire Crinetics in $10B foray into endocrine disease drugs"
              },
              {
                "id": 140829736,
                "url": "https://finnhub.io/api/news?id=e0487e79552e4d97446c9c81ed31eec4e8cb9d5ffc1b91a1f08090dd08181a5c",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2247479872/image_2247479872.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals Incorporated’s $10B Crinetics Pharmaceuticals, Inc. buy adds PALSONIFY & a Phase 3 CAH asset. Click for more on VRTZX and CRNX stock.",
                "category": "company",
                "datetime": 1783415710,
                "headline": "Vertex To Acquire Crinetics For ~$10bn - What Investors Should Know"
              },
              {
                "id": 140828404,
                "url": "https://finnhub.io/api/news?id=200b597be5b9a31e4658b2e0199b272d24a4abcecad9634f0ee5e57ba86087b2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "In a world where many businesses have shaky balance sheets, some have ignored the crowd and exercised prudence. These cash-heavy companies shine bright for their financial discipline, resilience, and ability to generate solid returns.",
                "category": "company",
                "datetime": 1783412323,
                "headline": "3 Cash-Heavy Stocks with Promising Prospects"
              },
              {
                "id": 140832343,
                "url": "https://finnhub.io/api/news?id=a911d9e49ae3315a4eb192918505313e84961bf09078b0c391a960a3a6296fd3",
                "image": "https://image.cnbcfm.com/api/v1/image/108218536-1761745666275-gettyimages-2225995430-img_9520.jpeg?v=1761745710&w=1920&h=1080",
                "source": "CNBC",
                "related": "VRTX",
                "summary": "These are the stocks posting the largest moves in early trading.",
                "category": "company",
                "datetime": 1783409181,
                "headline": "Stocks making the biggest moves premarket: Fiserv, Crinetics Pharmaceuticals, Micron & more"
              },
              {
                "id": 140834391,
                "url": "https://finnhub.io/api/news?id=e4c8f1e19b3613fd9f004f952e570bc3810d5899aab6456735f82122c6df73c3",
                "image": "",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "Baird  analyst Brian Skorney   maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Underperform and raises the price target from $330 to $350.",
                "category": "company",
                "datetime": 1783407241,
                "headline": "Baird Maintains Underperform on Vertex Pharmaceuticals, Raises Price Target to $350"
              },
              {
                "id": 140830640,
                "url": "https://finnhub.io/api/news?id=413aa9730aa18cba5d74ad66df0c1cbd03e28bf4c3ab224296e040b3b81b9294",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/07/Section-Of-A-Financial-Newspaper-Titled-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) rose in pre-market trading after being acquired by Vertex Pharmaceuticals (NASDAQ: VRTX) for $85/share.",
                "category": "company",
                "datetime": 1783399774,
                "headline": "Why Crinetics Pharmaceuticals Shares Are Trading Higher By 99%; Here Are 20 Stocks Moving Premarket"
              },
              {
                "id": 140827624,
                "url": "https://finnhub.io/api/news?id=95526ead49aa5e48af33333c3ab040bf6a80ab2af0965c18abb7c6187c070e76",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals Incorporated (VRTX) M&A Call July 6, 2026 4:30 PM EDTCompany ParticipantsSusie Lisa - Senior Vice President of Investor...",
                "category": "company",
                "datetime": 1783395149,
                "headline": "Vertex Pharmaceuticals Incorporated (VRTX) M&A Call Transcript"
              },
              {
                "id": 140825998,
                "url": "https://finnhub.io/api/news?id=8f7f628dd5cb5beeaf519272885c85adf58f740ac49355edfa785568f88e9d2a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "The deal values Crinetics at $85 per share in cash, representing a potential upside of about 100% from the stock’s closing price on Monday.",
                "category": "company",
                "datetime": 1783382832,
                "headline": "CRNX Stock Soars Nearly 100% After-Hours On Vertex's $10B Acquisition"
              },
              {
                "id": 140824488,
                "url": "https://finnhub.io/api/news?id=1ad42bf3c12f8e999efc66013ac3d00612256709a69fdf09bb45c96bfc6dfaa6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Crinetics stock nearly doubled late Monday after Vertex Pharmaceuticals pledged $10 billion to buy the endocrinology-focused biotech company.",
                "category": "company",
                "datetime": 1783373441,
                "headline": "Vertex Pharma Makes A $10 Billion Deal; Crinetics Stock Doubles"
              },
              {
                "id": 140824128,
                "url": "https://finnhub.io/api/news?id=755bfac8086b55458ed003b38133dd776e18096e6e6946c3c4a4bc64ae17e627",
                "image": "https://www.chartmill.com/images/uploads/CM_Aftermarket_Movers_Small_free_e077945a19.webp",
                "source": "ChartMill",
                "related": "VRTX",
                "summary": "As the regular session of the US market on Monday comes to an end, let's delve into the after-hours session and discover the top S&P500 gainers and losers shaping the post-market sentiment.",
                "category": "company",
                "datetime": 1783371901,
                "headline": "Which S&P500 stocks are showing activity after the closing bell on Monday?"
              },
              {
                "id": 140825630,
                "url": "https://finnhub.io/api/news?id=abdac01b422be4d6fb252de6cefbe279f3cf3c8bebbb2f71f9b14be2a3bcde7d",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "VRTX",
                "summary": "2026-07-06. The following slide deck was published by Vertex Pharmaceuticals Incorporated in conjunction with this event.",
                "category": "company",
                "datetime": 1783370581,
                "headline": "Vertex Pharmaceuticals Incorporated (VRTX) Crinetics Pharmaceuticals, Inc. - M&A Call - Slideshow"
              },
              {
                "id": 140824489,
                "url": "https://finnhub.io/api/news?id=97a805cba3b660d2305c1f6bfdd5e4d85101af8e37e49a3ea5fdf0435e5beb3d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Investing.com -- Vertex Pharmaceuticals Incorporated announced Monday it will acquire Crinetics Pharmaceuticals, Inc. for $85.00 per share in cash, representing a total equity value of approximately $10.0 billion, or approximately $8.8 billion net of estimated cash acquired.",
                "category": "company",
                "datetime": 1783370538,
                "headline": "Crinetics soars on $10B acquisition by Vertex"
              },
              {
                "id": 140824490,
                "url": "https://finnhub.io/api/news?id=f80f6a01472ad5b2ef2125296fb76fc26f563d6e55853bfcce82cc755da464dc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "BOSTON & SAN DIEGO, July 06, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Crinetics for $85.00 per share in cash, for a total equity value of approximately $10.0 billion, or approximately $8",
                "category": "company",
                "datetime": 1783368240,
                "headline": "Vertex to Acquire Crinetics Pharmaceuticals"
              },
              {
                "id": 140823681,
                "url": "https://finnhub.io/api/news?id=2cd0c8d781540a271607d3b32056bd6fd82b82692fe651d966f6f769478e151e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "The pharma stock is up around 17% this year.",
                "category": "company",
                "datetime": 1783366227,
                "headline": "Vertex Pharmaceuticals Stock Is Soaring and at a New All-Time High. Could It Still Be Heading Even Higher?"
              },
              {
                "id": 140824632,
                "url": "https://finnhub.io/api/news?id=dc25122ecf699006738711ce1c6cdda4bb1b51aa37e622132cac1d5f754a2f97",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/06/Financial-Graph-With-Uptrend-Line-Techno.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "Crinetics Pharmaceuticals shares are trading higher in Monday's after-hours session after the company announced it will be acquired by Vertex.",
                "category": "company",
                "datetime": 1783355455,
                "headline": "Crinetics Pharmaceuticals Stock Doubles After The Close: Here's Why"
              },
              {
                "id": 140832624,
                "url": "https://finnhub.io/api/news?id=7f269767c6825e98a6c9dfbacbf7259fd8b2322730ab1472d38aef870b64c14d",
                "image": "https://image.cnbcfm.com/api/v1/image/108331088-17833693631783369361-46999471812-1080pnbcnews.jpg?v=1783369362&w=1920&h=1080",
                "source": "CNBC",
                "related": "VRTX",
                "summary": "CNBC's Angelica Peebles reports on Vertex Pharmaceuticals' acquisition of Crinetics.",
                "category": "company",
                "datetime": 1783355415,
                "headline": "Vertex to buy Crinetics in an all-cash deal valued at $10 billion"
              },
              {
                "id": 140824633,
                "url": "https://finnhub.io/api/news?id=0801baa9184b0b2ebbbdacfacf2275f81385ecb1d7f9b7402fbca81153cf89f0",
                "image": "",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for",
                "category": "company",
                "datetime": 1783353929,
                "headline": "Vertex Pharmaceuticals Agrees To Acquire Crinetics Pharmaceuticals For $85/Share In Cash"
              },
              {
                "id": 140821153,
                "url": "https://finnhub.io/api/news?id=09bfe4632fd1ad6a2881612f9c9f2461ad34732819ed3d53e6b73b3d018413bc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals today announced that it has signed a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for PrALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), a new triple combination therapy for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. This LOI follows the positive reimbursement recommendati",
                "category": "company",
                "datetime": 1783347720,
                "headline": "Vertex Signs Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance for ALYFTREK for the Treatment of Cystic Fibrosis"
              },
              {
                "id": 140820124,
                "url": "https://finnhub.io/api/news?id=85d6f3740d72f24a15b0a7b2d9ec9bff61db5038ada9e3b50a657ba731c67b30",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "One company leads in gene-editing approvals, while the other targets surging demand in metabolic treatments. Here’s how their financials and risk profiles compare.",
                "category": "company",
                "datetime": 1783338901,
                "headline": "CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 140823400,
                "url": "https://finnhub.io/api/news?id=270e3f1f5c7a719535b7a0ef0ac7200ec36c60a0b0968b79f9c8b67cc5529ce6",
                "image": "",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals today announced that it has signed a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for PrALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), a new triple combination",
                "category": "company",
                "datetime": 1783333645,
                "headline": "Vertex Signs LOI With The Pan-Canadian Pharmaceutical Alliance For PrALYFTREK For The Treatment Of Cystic Fibrosis In Patients Aged 6 Years And Older Who Have At Least One F508del Mutation Or Another Responsive Mutation In The CFTR Gene"
              },
              {
                "id": 140812060,
                "url": "https://finnhub.io/api/news?id=3b0b044bcb0249279703d18169b8d8cc9b6f3b02d6d8753f2dcbbb75669f29ee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "This big biotech stock doesn't get the hype that SpaceX does. But it could be the smarter bet right now.",
                "category": "company",
                "datetime": 1783242240,
                "headline": "While SpaceX Gets the Headlines, Smart Investors Are Loading Up on This Stock Instead"
              },
              {
                "id": 140800083,
                "url": "https://finnhub.io/api/news?id=164514ebcd3205bc9d7843b1a883a6d608485a78053c7498fd497b1b6ed57149",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "FDA approved expanded use of CASGEVY for children as young as two years with sickle cell disease and transfusion-dependent beta thalassemia. The approval makes CASGEVY the first gene therapy of its kind available to this pediatric group in the U.S. Vertex Pharmaceuticals estimates that roughly 5,500 additional children in the U.S. may now be eligible for this one-time genetic treatment. Vertex Pharmaceuticals, traded as NasdaqGS:VRTX, now has FDA approval to offer CASGEVY to a much younger...",
                "category": "company",
                "datetime": 1783088093,
                "headline": "Vertex Pharmaceuticals (VRTX) Wins FDA Approval To Treat Two Year Olds With CASGEVY"
              },
              {
                "id": 140800084,
                "url": "https://finnhub.io/api/news?id=d9b3f70e5cbfec650076df510039c9b294de258754fa8ceab3fefe6e371539da",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "According to the average brokerage recommendation (ABR), one should invest in Vertex (VRTX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?",
                "category": "company",
                "datetime": 1783085407,
                "headline": "Wall Street Bulls Look Optimistic About Vertex (VRTX): Should You Buy?"
              },
              {
                "id": 140799650,
                "url": "https://finnhub.io/api/news?id=92522537e3d1ab8ebfeed0d9f2ee31c2a2644d7b65f7cadb0b4eef4e0f969b4b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Arcutis doubled revenue last year while Vertex delivered strong profits and cash flow. Explore how each company stacks up on growth, risk, and value.",
                "category": "company",
                "datetime": 1783083440,
                "headline": "Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026?"
              },
              {
                "id": 140795901,
                "url": "https://finnhub.io/api/news?id=326cbb0a582da9491c50a786271e36ae869915ccb646b59899c45d78f7507188",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "The fresh FDA approval allows the use of the cell therapy in patients as young as two years old with sickle cell disease (SCD) who have recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia (TDT).",
                "category": "company",
                "datetime": 1783027004,
                "headline": "CRSP, VRTX Stocks Surge As FDA Clears Casgevy For Children Ages 2 And Up"
              },
              {
                "id": 140791500,
                "url": "https://finnhub.io/api/news?id=e34d320bd39ab0f00f5a7ffcf504ea6725eaf7e11d8bd5a03965f29079d17aed",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "VRTX gets FDA approval to expand Casgevy use in patients aged two and older with SCD or TDT, a first for genetic therapies in both inherited blood disorders.",
                "category": "company",
                "datetime": 1783003320,
                "headline": "Vertex Gets FDA Nod for Expanded Use of Casgevy in SCD & TDT"
              },
              {
                "id": 140793835,
                "url": "https://finnhub.io/api/news?id=9de6ce5002b7805dc687f97dd84bceebcd63874c1741f7a30efa1f76e9693810",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/02/Vertex-Pharmaceuticals-Inc.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "FDA expands Vertex Casgevy label to patients aged 2 and older, making about 5,500 more U.S. children eligible for the therapy.",
                "category": "company",
                "datetime": 1782981204,
                "headline": "Vertex Says Casgevy Label Expansion Opens Treatment to 5,500 More Us Children"
              },
              {
                "id": 140793836,
                "url": "https://finnhub.io/api/news?id=cd330b74858327a97ff60712c078826336c56cb85c2d5295e33bb3c5c671d39f",
                "image": "",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "- First and only approved genetic therapy to treat children as young as 2 years for both severe sickle cell disease and transfusion-dependent beta thalassemia -- Approximately 5,500 additional children in the U.S. are",
                "category": "company",
                "datetime": 1782961765,
                "headline": "Reported Earlier, Vertex Wins FDA Approval Expanding CASGEVY Use To Children As Young As 2 With Severe Sickle Cell Disease Or Beta Thalassemia"
              },
              {
                "id": 140786581,
                "url": "https://finnhub.io/api/news?id=52c78d706a9db26b953f778e31d58f1170246e7fa12bbe322dba66842da12231",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "BOSTON, July 01, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the U.S. Food and Drug Administration (FDA) has approved expanded use of CASGEVY® (exagamglogene autotemcel) for the treatment of people ages 2 years and older with either sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) or transfusion-dependent beta thalassemia (TDT). CASGEVY is the first approved genetic therapy indicated for children as young as 2 years for both SCD and TDT.",
                "category": "company",
                "datetime": 1782950280,
                "headline": "Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia"
              },
              {
                "id": 140785323,
                "url": "https://finnhub.io/api/news?id=268614001cd2f46dfa4636da0a14a563496e8b276f8fd548a34621718f20b41e",
                "image": "",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-young-children-sickle-cell-disease",
                "category": "company",
                "datetime": 1782927315,
                "headline": "FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease; The FDA Granted The Approval To Vertex Pharmaceuticals"
              },
              {
                "id": 140782680,
                "url": "https://finnhub.io/api/news?id=f809eb95c2ba749784fb8f26e5efe1123f3d87eeb7903960514ce5cfb6aba57e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Dyne pursues rare disease breakthroughs while Vertex leverages blockbuster profits for pipeline expansion, how do their risk profiles and financials compare?",
                "category": "company",
                "datetime": 1782921522,
                "headline": "Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026?"
              },
              {
                "id": 140780793,
                "url": "https://finnhub.io/api/news?id=a48c3c90f16d60a978311a8ebd93c83c1fe2fb8e887de08d8f69040a7579da8c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
                "category": "company",
                "datetime": 1782910805,
                "headline": "Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know"
              },
              {
                "id": 140791501,
                "url": "https://finnhub.io/api/news?id=604e93de23c02c115e906456182d5a81d131254c9a5357857f43853429f14814",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Elsewhere, Otsuka’s kidney drug hit the goal of a confirmatory trial and Vertex’s CRISPR sickle cell drug secured expanded approval.",
                "category": "company",
                "datetime": 1782905340,
                "headline": "BridgeBio gets funding for drug launch; United buys into cell therapy"
              },
              {
                "id": 140775334,
                "url": "https://finnhub.io/api/news?id=767475560b340dce1e6b69feccc5e61184cfb6c2e1dcc7efa801ce5ee94fff44",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, June 30, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) announces that it intends to complete a non-brokered private placement financing (the “Private Placement”) of a minimum of 2,280,000 units of the Company (the “Units”) and up to a maximum of 5,000,000 Units, at a price of $0.30 per Unit, for minimum gros",
                "category": "company",
                "datetime": 1782854040,
                "headline": "Vortex Energy Corp. Announces LIFE Offering"
              },
              {
                "id": 140773593,
                "url": "https://finnhub.io/api/news?id=9502be0482ecf2e1d68e675a87ad1c320d7c07ebe8fa20c0aa5b23f706e0de2d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Wrapping up Q1 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers.",
                "category": "company",
                "datetime": 1782835861,
                "headline": "Therapeutics Stocks Q1 Recap: Benchmarking Vertex Pharmaceuticals (NASDAQ:VRTX)"
              },
              {
                "id": 140772314,
                "url": "https://finnhub.io/api/news?id=e10497ea38e4fbad71eb7072d597a29bb43582fc3c78ed5ce80d21a5cf7c2964",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2194222148/image_2194222148.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals Incorporated offers predictable CF cash flows and pipeline catalysts in pain, hematology & renal (Pove for IgAN). Click for this VRTX update.",
                "category": "company",
                "datetime": 1782810196,
                "headline": "Vertex Pharmaceuticals Has One Of The Widest And Most Durable Moats In Biotech"
              },
              {
                "id": 140772337,
                "url": "https://finnhub.io/api/news?id=371f70abd8914deedecf42e4c1b626dc98debadaf098ed821b53ba58c6586376",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/30/Experts-Stress-Individual-Strategy.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "Jim Lebenthal recommends Vertex Pharmaceuticals in the healthcare sector. Jenny Van Leeuwen picks Verizon, IBM is down 18%, Joseph Terranova chooses Corning.",
                "category": "company",
                "datetime": 1782805824,
                "headline": "IBM, Verizon, Corning And A Health Care Stock On CNBC’s ‘Final Trades’"
              },
              {
                "id": 140762673,
                "url": "https://finnhub.io/api/news?id=3484cd2804e17574e52f5dc75211e2bdaed85ba2dc7204ea87eeb546c4c90f85",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Recently published Nephrotic Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, nephrotic syndrome emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].",
                "category": "company",
                "datetime": 1782743460,
                "headline": "Nephrotic Syndrome Market Set for Robust Growth During the Forecast Period (2026-2036), Driven by Emerging Therapies and Expanding Research | DelveInsight"
              },
              {
                "id": 140763495,
                "url": "https://finnhub.io/api/news?id=4709d5ca306bbc1855ff81a039eead68fd90197ec3bd3dd346939cc5bdb0782e",
                "image": "https://image.cnbcfm.com/api/v1/image/108328225-17827525071782752505-46850070738-1080pnbcnews.jpg?v=1782752506&w=1920&h=1080",
                "source": "CNBC",
                "related": "VRTX",
                "summary": "CNBC’s “Halftime Report” Investment Committee discusses their top stocks to watch for the second half of the day's trading session.",
                "category": "company",
                "datetime": 1782738813,
                "headline": "Final Trades: Vertex Pharma, Verizon, IBM and Corning"
              },
              {
                "id": 140768150,
                "url": "https://finnhub.io/api/news?id=3dc68a4a1dcaa2ec5804c683de8351e726b2d77494d28eccc55d3c4ed76b593a",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_3.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 8.53% on an annualized basis producing an average annual return of 19.73%. Currently, Vertex Pharmaceuticals has a market",
                "category": "company",
                "datetime": 1782732639,
                "headline": "$100 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today"
              },
              {
                "id": 140745296,
                "url": "https://finnhub.io/api/news?id=51bf5a48b04117b7a6c58f6383c5d05d5fab39ef4742ac35838beb847ec58dd3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "From gene-editing breakthroughs to blockbuster cystic fibrosis drugs, these two industry leaders present sharply contrasting financials and risk profiles.",
                "category": "company",
                "datetime": 1782555603,
                "headline": "CRISPR Therapeutics AG vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 140741534,
                "url": "https://finnhub.io/api/news?id=ed5abd1fbe9d526d8fc5c2f40585991dc4b9fad448ebf9c38b643cbc90d3c448",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $491.34, denoting a +2.32% move from the preceding trading day.",
                "category": "company",
                "datetime": 1782510603,
                "headline": "Why the Market Dipped But Vertex Pharmaceuticals (VRTX) Gained Today"
              },
              {
                "id": 140734904,
                "url": "https://finnhub.io/api/news?id=ba405cbb5351c150f0bceddf11fff95636a06e4fa33d4125056aa50956322117",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2250056975/image_2250056975.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "VRTX",
                "summary": "Beam Therapeutics could have a moat around its business due to Risto-cel showing competitive efficacy. See why BEAM stock is downgraded to a hold.",
                "category": "company",
                "datetime": 1782463200,
                "headline": "Beam Therapeutics: A Better Entry Point Is Likely Coming (Rating Downgrade)"
              },
              {
                "id": 140714117,
                "url": "https://finnhub.io/api/news?id=8754b6c870f15453540296beaa40b34d9c900e41320a44ce7052cf06fa530b35",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "HOUSTON, June 24, 2026--Vertex Energy, Inc. (\"Vertex\" or the \"Company\") today announced it is advancing a project at its Mobile, Alabama refinery to produce crude-derived conventional Group III base oils through the Company’s existing hydrocracker and related processing infrastructure, providing lubricant manufacturers and blenders with an additional domestic source of high-quality Group III supply.",
                "category": "company",
                "datetime": 1782309600,
                "headline": "Vertex Energy Announces 6,000 bpd Group III Base Oil Expansion Project"
              },
              {
                "id": 140712577,
                "url": "https://finnhub.io/api/news?id=253be52f81d05c6e520168b36d6171d836afc0c3383f8076989054b7615008b7",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2219926893/image_2219926893.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals: R&D wins beyond cystic fibrosis, with the povetacicept FDA decision coming for IgA nephropathy. Click for this VRTX update.",
                "category": "company",
                "datetime": 1782292113,
                "headline": "Vertex Pharmaceuticals: Povetacicept May Redefine Growth Narrative (Rating Upgrade)"
              },
              {
                "id": 140714084,
                "url": "https://finnhub.io/api/news?id=c642c31397f9ef461dafed417b03bb5b4adf8b4c322ad403f6dd4c72035448ee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "The iShares Nasdaq Biotechnology ETF (IBB) is trading just 1.47% below its 52-week high, signaling a potential multi-year sector breakout.",
                "category": "company",
                "datetime": 1782229800,
                "headline": "The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch."
              },
              {
                "id": 140704866,
                "url": "https://finnhub.io/api/news?id=6a016defe1b9dc53f0a16467941078ed767221dc5a1d439272f088d00e57048c",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2194222145/image_2194222145.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "VRTX",
                "summary": "After lagging expectations during recent market volatility, the healthcare sector is showing signs of strength. TD Asset Management's Jacky He explains what's driving the sector’s rebound.",
                "category": "company",
                "datetime": 1782226200,
                "headline": "Healthcare's Quiet Comeback: Innovation, Obesity Drugs And New Opportunities"
              },
              {
                "id": 140701556,
                "url": "https://finnhub.io/api/news?id=f4edb5917bb8a5297a6ee5ae6fe967df2df43b5324d397588ee440ab24e4425a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "If you are wondering whether Vertex Pharmaceuticals is priced fairly after its recent run, a good starting point is understanding what the current share price implies about future expectations. The stock last closed at US$466.79, with returns of 3.0% over the past week, 7.4% over the past month, 3.2% year to date, 3.7% over one year, 34.5% over three years and 137.2% over five years. This performance raises questions about how much of the story is already reflected in the price. Recent...",
                "category": "company",
                "datetime": 1782220375,
                "headline": "Vertex Pharmaceuticals (VRTX) Stock After Strong Multi‑Year Run Is The Price Still Reasonable"
              },
              {
                "id": 140701557,
                "url": "https://finnhub.io/api/news?id=736e533818ca750eccbea95344aec246aef570b83d9c5b45fdb4110d01859432",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals recently reported Phase 3 data showing that its CRISPR-based therapy CASGEVY delivered strong clinical benefits and a consistent safety profile in children ages 5–11 with severe sickle cell disease and transfusion-dependent beta thalassemia, with all evaluable patients achieving the main trial goals. This pediatric dataset, presented at the European Hematology Association Congress and published in the New England Journal of Medicine, supports Vertex’s regulatory push...",
                "category": "company",
                "datetime": 1782216509,
                "headline": "Positive Pediatric CASGEVY Data Might Change The Case For Investing In Vertex Pharmaceuticals (VRTX)"
              },
              {
                "id": 140700583,
                "url": "https://finnhub.io/api/news?id=2e537296495676e7e9129ba974d1a66699556185dc39d75aa97ea4e70171a72e",
                "image": "https://www.chartmill.com/images/uploads/Affordable_Growth_500_264px_webp_add6a3aa59.webp",
                "source": "ChartMill",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (VRTX) fits the GARP strategy with a Growth Rating of 7, reasonable valuation below industry peers, strong profitability, and zero debt, making it a compelling growth-at-a-reasonable-price candidate.",
                "category": "company",
                "datetime": 1782214236,
                "headline": "Vertex Pharmaceuticals (NASDAQ:VRTX): A GARP Growth Stock with Reasonable Valuation and Strong Fundamentals"
              },
              {
                "id": 140700953,
                "url": "https://finnhub.io/api/news?id=d9e536315b97c3074e2a19053e6928ca3cc7f6cc86cc2c744f0b11afce046908",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1928832415/image_1928832415.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "VRTX",
                "summary": "Moderna, Inc. shifts beyond Covid with mRNA vaccines like mFlusiva, combo shots, and oncology catalysts. Click for more on MRNA stock prospects.",
                "category": "company",
                "datetime": 1782202884,
                "headline": "Moderna: The Comeback Is Now In Full Swing"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 2,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.6,
            "source_article_count": 134,
            "discarded_article_count": 106
          },
          "sentimentPoints": 4
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 15.3,
        "grade": "較差",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 2.2,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 2.2,
            "vcp_reason": "波幅收縮(21.1%→6.6%)；跌縮量(近10日6日)；站上MA50；Ready=Y；Confirm=N",
            "vcp_metrics": {
              "up_days": 3,
              "vol_ref": 1774136.6666666667,
              "down_days": 6,
              "vcp_ready": true,
              "above_ma50": true,
              "avg_vol_10": 1341350,
              "avg_vol_20": 1918360,
              "avg_vol_30": 1774136.6666666667,
              "range_pct_10": 0.06588594192129146,
              "range_pct_20": 0.13542871449769572,
              "range_pct_30": 0.21110146239490557,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": false,
              "contraction_ok": true,
              "down_shrink_ok": true,
              "up_expand_days": 0,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.756057876037359,
              "dist_to_20d_high": 0.11351581739711127,
              "down_shrink_days": 6,
              "breakout_level_20d": 533.66998,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.3121055684495413
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 0.8,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0.4,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 0.4
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "一般",
        "items": {
          "position": {
            "score": 1.3,
            "details": {
              "atrPct": 3.09666239486493,
              "turnoverUsdM": 617.743885536944,
              "liquidityPoints": 0.6,
              "volatilityPoints": 0.7
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.VRTX",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 443.79,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 1,
              "rsi_score": 2.5,
              "macd_score": 1.5,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1,
            "stop_loss_percent": 6.2,
            "take_profit_price": 501.3889,
            "target_multiplier": 1.9,
            "technical_strength": 1.53,
            "take_profit_percent": 6
          },
          "positionPoints": 1.3,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 6.19332478972986,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 92.86,
    "atr": {
      "atr": 14.65,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 4,
      "atr_pct": 3.1
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": -106.83
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "平衡",
      "score": 4,
      "value": 0.0226
    },
    "kdj": {
      "d": 24.1,
      "j": 20.73,
      "k": 22.98,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "超賣或超買風險",
      "score": 2,
      "value": 21.66
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 4,
      "trend": "弱勢",
      "value": 14894664,
      "recentSlope": -123023.6,
      "previousSlope": 570920
    },
    "rsi": 16.3,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 497.1893,
      "position": "SAR喺價上",
      "distancePct": 5.09,
      "previousTrend": "下降"
    },
    "ma50": 463.7164,
    "macd": {
      "macd": 2.9753210885762087,
      "trend": "中性偏多",
      "signal": 7.4137248618246705,
      "histogram": -4.438403773248462
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 494.0322,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "空升",
      "ratio": 0.69,
      "score": 2,
      "avgVolume": 1906148,
      "currentVolume": 1305764
    },
    "derived": {
      "ma20": 491.9795,
      "ma50": 463.7164,
      "prevClose": 472.57,
      "avgVolume10": 1261236,
      "avgVolume20": 1906148,
      "changePercent": 0.11,
      "avgVolumeForScore": 1906148
    },
    "ma_cross": {
      "ma20": 491.9795,
      "ma50": 463.7164,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 492.085,
      "prevMa50": 462.958,
      "spreadPct": 6.09,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 458.3951,
      "upper": 525.5639,
      "position": "中間"
    },
    "rsi_short": 42.31,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.69
    }
  }
}

{
  "close": 473.09,
  "volume": 1305764,
  "changePercent": 0.11
}